Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) were up 1.3% during mid-day trading on Thursday following insider buying activity. The stock traded as high as $10.49 and last traded at $10.03. Approximately 539,758 shares traded hands during mid-day trading, a decline of 33% from the average daily volume of 811,331 shares. The stock had previously closed at $10.16.

Specifically, insider Lonnel Coats acquired 30,000 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was acquired at an average price of $12.54 per share, with a total value of $376,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Public Equities L.P. Invus acquired 180,727 shares of the firm’s stock in a transaction on Friday, November 17th. The stock was purchased at an average cost of $10.11 per share, with a total value of $1,827,149.97. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 945,353 shares of company stock valued at $9,304,953. 5.77% of the stock is owned by insiders.

Several analysts have issued reports on LXRX shares. Wedbush reissued an “ourperform” rating and issued a $39.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Monday, August 7th. Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Cowen and Company reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $21.00 target price on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. Lexicon Pharmaceuticals has a consensus rating of “Hold” and an average target price of $28.75.

The company has a quick ratio of 1.65, a current ratio of 1.66 and a debt-to-equity ratio of 1.09.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.07. The company had revenue of $26.94 million for the quarter, compared to analyst estimates of $27.97 million. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. Lexicon Pharmaceuticals’s revenue was down 2.8% compared to the same quarter last year. During the same period last year, the company posted ($0.35) earnings per share. research analysts expect that Lexicon Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Cubist Systematic Strategies LLC acquired a new stake in Lexicon Pharmaceuticals in the third quarter valued at approximately $149,000. Parametric Portfolio Associates LLC acquired a new stake in Lexicon Pharmaceuticals in the second quarter valued at approximately $182,000. C WorldWide Group Holding A S lifted its stake in shares of Lexicon Pharmaceuticals by 49.6% during the third quarter. C WorldWide Group Holding A S now owns 16,146 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 5,353 shares during the period. First Mercantile Trust Co. lifted its stake in shares of Lexicon Pharmaceuticals by 11.2% during the second quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock worth $201,000 after buying an additional 1,227 shares during the period. Finally, Cim Investment Mangement Inc. acquired a new stake in shares of Lexicon Pharmaceuticals during the second quarter worth $262,000.

WARNING: This story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/lexicon-pharmaceuticals-inc-lxrx-trading-up-1-3-following-insider-buying-activity/1710771.html.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.